Implanon
Generic name: etonogestrel
Treatment for: Birth Control
Akzo Nobel’s Contraceptive Implanon Receives “Approvable” Status from the FDA
ARNHEM, The Netherlands, November 3, 2004 – Akzo Nobel’s human pharmaceutical business Organon announced today that the U.S. Food and Drug Administration (FDA) has granted the contraceptive Implanon (etonogestrel sub-dermal implant) “approvable” status.
Implanon is a small, flexible rod, about the size of a matchstick, that contains etonogestrel, a progestin. Once inserted under the skin, the rod continually releases a low dose of etonogestral into the bloodstream, which provides contraceptive protection. Implanon is one of the innovative contraceptive products developed by Organon in recent years.
“Organon recognizes the market need for diversity in the contraceptive marketplace and Implanon will provide women in the U.S. with a new method of contraception,” said Toon Wilderbeek, President of Organon International and Member of Akzo Nobel’s Board of Management.
Posted: November 2004
Related articles
- FDA Approves Implanon (etonogestrel implant) for Contraception - July 18, 2006
- Organon Receives Approvable Letter From FDA for Contraceptive Implant - June 21, 2005
Implanon (etonogestrel) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
